CAR T-Cell therapy Market Growth Statistics & Future Prospects by 2031

According to a new report published by Allied Market Research, titled, "CAR T-Cell therapy Market," The car t-cell therapy market was valued at $1.7 billion in 2021, and is estimated to reach $6.1 billion by 2031, growing at a CAGR of 13.5% from 2022 to 2031.

The advantages of CAR T-cell therapy over conventional drugs include the destruction of cancer cells using the immune system and early recovery. In addition, CAR T-cell therapy survives in the body for a long time. It has the ability to recognize and target cancer cells even if the cancer returns. Therefore, CAR T-cell therapy is used to treat lymphoma, acute lymphocytic leukemia and multiple myeloma blood cancer.

♦ 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅:
https://www.alliedmarketresearch.com/request-sample/17358

Key Benefits for Stakeholders -

• This report provides a quantitative analysis of market segments, current trends, strategies and capabilities of Car T Cell Therapy market research from 2021 to 2031 to identify the market opportunities of T cell therapy for cars.
• In-depth analysis of the car t-cell therapy market segmentation assists to determine the prevailing market opportunities.
• Market analysis and information related to key drivers, restraints and opportunities are provided. • Porter's Five Forces Analysis identifies the capabilities of buyers and suppliers to enable stakeholders to make profitable business decisions and strengthen the network of buyers.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• The report includes regional and global car t-cell therapy market analysis, key players, market segments, application areas and Market growth strategies.

Major Key market players covered in the report -

Autolus Therapeutics,
Bluebird bio, Inc.,
Bristol-Myers Squibb,
Caribou Biosciences, Inc.,
Cartesian Therapeutics, Inc.,
Celgene Corporation,
Cellectis,
Celyad Oncology,
Gilead Sciences, Inc. (Kite Pharma Inc.),
Intellia Therapeutics,
Juno Therapeutics, Inc.,
Merck & Co., Inc.,
Miltenyi Biotech,
Novartis AG,
Pfizer, Inc.,
Sorrento Therapeutics, Inc.

♦ 𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.alliedmarketresearch.com/purchase-enquiry/17358

However, the commercialization of CAR T-cell therapy has faced obstacles, due to strict government regulations on the acceptance of CAR T-cell therapy. Side effect of CAR T-cell therapy and high cost of treatment hinders market growth.

TABLE OF CONTENT -

CHAPTER 1 - INTRODUCTION:
1.1. Report description
1.2. Key market segments
1.3. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 - EXECUTIVE SUMMARY:
2.1. Key findings of the study
2.2. CXO Perspective

Market: By Region Outlook
• North America (U.S., Canada, Mexico)
• Europe (UK, Germany, France, Spain, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific)
• LAMEA (Brazil, South Africa, Turkey, Saudi Arabia, Rest of LAMEA)
Based on the indicators, the Lymphoma segment will generate the highest revenue in 2021 due to the high number of CAR T-cell therapies approved for the treatment of various types of lymphoma with a large target population. The acute lymphocytic leukemia segment is expected to witness the highest CAGR during the forecast period, due to the increase in CAR T-cell therapies for the treatment of all people and the expected launch of these drugs for the treatment of LAL.

♦ 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐅𝐨𝐫 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧:
https://www.alliedmarketresearch.com/request-for-customization/17358

Regionally, in the CAR-T cell therapy industry, North America generated the most revenue in 2021, driven by the strong presence of key players in the availability of approved therapies and high adoption in CAR-T therapy. Asia-Pacific is expected to witness the highest CAGR during the forecast period due to the increase in CAR T-cell therapy, expected launch of CART drugs and increase in the target population.

Frequently Asked Questions?

Q1. What is the total market value of car t-cell therapy market report?

Q2. Which are the top companies holding the market share in car t-cell therapy market?

Q3. Which are the largest regions for this Market?

Q4. What is the leading technology of car t-cell therapy market?

Q5. What are the major drivers for this specific Market?

♦ 𝐂𝐡𝐞𝐜𝐤 𝐎𝐮𝐭 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐇𝐞𝐫𝐞:

Pacemaker Market - https://www.alliedmarketresearch.com/pacemaker-market

South Korea ECG Market - https://www.alliedmarketresearch.com/south-korea-ecg-market

Medical Spa Market - https://www.alliedmarketresearch.com/medical-spa-market

Hemodialysis Market - https://www.alliedmarketresearch.com/hemodialysis-market

Cryotherapy Market - https://www.alliedmarketresearch.com/cryotherapy-market-A11930

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us -

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.